Company Overview
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
Why Investors Should Care
Generates a return on equity of 76.7%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -1.82% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +5.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)54.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 76.7%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KARD Kardigan, Inc. PHARMA | 21.60 | -6.99 | $2.02B | 0.00% | -57.11% | 76.67% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 26.08M | 58.71M |
| Operating Income | -26.08M | -58.71M |
| EBITDA | -25.33M | -56.59M |
| Interest Expense | - | - |
| Pretax Income | -22.19M | -56.07M |
| Tax Provision | -4.17M | 0 |
| Net Income | -18.02M | -56.07M |
| Diluted EPS | -0.29 | -0.90 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 96.66M | 201.84M |
| Operating Income | -96.66M | -201.84M |
| EBITDA | -96.31M | -195.99M |
| Interest Expense | - | - |
| Pretax Income | -88.66M | -196.45M |
| Tax Provision | 0 | -4.51M |
| Net Income | -88.66M | -191.94M |
| Diluted EPS | -1.42 | -3.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 63.53M | 390.94M |
| Current Assets | 50.32M | 345.35M |
| Cash & Equivalents | 49.40M | 108.99M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 146.72M | 641.28M |
| Current Liabilities | 8.29M | 37.54M |
| Long Term Debt | - | - |
| Total Debt | 9.54M | 13.83M |
| Total Equity | -83.19M | -250.34M |
| Shares Outstanding | 89.34M | 89.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -18.82M | -151.06M |
| Investing Cash Flow | -36.42M | -237.04M |
| Financing Cash Flow | 105.01M | 447.81M |
| Capital Expenditure | -36.42M | -6.64M |
| Free Cash Flow | -55.24M | -157.70M |
| Net Change in Cash | 49.77M | 59.71M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 106.6% | 76.7% |
| ROCE % | -175.0% | -57.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRTG GPE, LLC | 18.09% | 16.92M | $281.50M |
| 2 | FMR, LLC | 9.53% | 8.91M | $148.25M |
| 3 | Perceptive Advisors Llc | 8.77% | 8.20M | $136.46M |
| 4 | T. Rowe Price Investment Management, Inc. | 4.50% | 4.21M | $70.01M |
| 5 | Capital Research Global Investors | 3.85% | 3.60M | $59.89M |
| 6 | JPMORGAN CHASE & CO | 1.92% | 1.79M | $29.80M |
| 7 | Alliancebernstein L.P. | 1.64% | 1.53M | $25.54M |
| 8 | Liberty Mutual Group Asset Management Inc. | 1.28% | 1.20M | $19.91M |
| 9 | Jennison Associates LLC | 0.97% | 903.58K | $15.04M |
| 10 | Paradigm Biocapital Advisors LP | 0.96% | 900.00K | $14.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KARD
Kardigan to Present at Two September Investor Conferences
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., September 02, 2026--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference…
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., August 11, 2026--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.…
2 ‘Strong Buy’ IPO Stocks JPMorgan Thinks Are Worth Watching
The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raised…
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., June 22, 2026--Kardigan announced the closing of its initial public offering.
Kardigan (KARD) Stock Price At $22 Raises Fresh Valuation Questions
Kardigan (KARD), a South San Francisco based biopharmaceutical company focused on cardiovascular medicines, recently drew investor attention after its stock closed at $22.00. This price implies a market value near $1.97b. See our latest ana…
Kardigan shares soar after Nasdaq debut
Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.
KARD — Frequently Asked Questions
What is the current share price of Kardigan, Inc. (KARD)?
As of 2026-09-19 21:16 PDT, Kardigan, Inc. (KARD) trades at $21.60 on NasdaqGM. Its 52-week range is $19.60 to $25.90.
What is the market capitalisation of KARD?
Kardigan, Inc. (KARD) has a market capitalisation of $2.02B on NasdaqGM.
What is the P/E ratio of KARD?
KARD trades at a trailing price-to-earnings (P/E) ratio of -6.99. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.53.
What is the return on equity (ROE) of KARD?
KARD has a return on equity (ROE) of 76.67%. Its return on capital employed (ROCE) is -57.11%.
Is KARD a good stock to buy?
This page provides a data-driven analysis of Kardigan, Inc. (KARD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.